Communication of the meeting of Transparency Council No. 8/2026 on 23 February 2026 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 8/2026 on 23 February 2026 during which the following resolutions were adopted:

1. At its meeting on 23 February 2026, the Transparency Council adopted position No. 25/2026 on the evaluation of Agamree (vamorol) under the drug program “Treatment of patients with Duchenne muscular dystrophy (DMD) (ICD-10: G71.0)”
2. At its meeting on 23 February 2026, the Transparency Council adopted position No. 26/2026 on the evaluation of Poltixa (apixabanum) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with at least one risk factor
3. At its meeting on 23 February 2026, the Transparency Council adopted opinion No. 21/2026 on the introduction of comprehensive changes to the content of drug program B.31 “Treatment of pulmonary arterial hypertension (ICD-10 I27, I27.0)”
4. At its meeting on 23 February 2026, the Transparency Council adopted position No. 27/2026 on the validity of issuing approvals for the reimbursement of Milupa Basic-P, a food product for special nutritional purposes, in a number of indications
5. At its meeting on 23 February 2026, the Transparency Council adopted opinion No. 22/2026 on the reimbursement of medicines containing the active substance sunitinibum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
6. At its meeting on 23 February 2026, the Transparency Council adopted opinion No. 23/2026 on the reimbursement of medicines containing the active substance everolimusum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics

Transparency Council meeting protocol >>